Extracellular Tuning of Mitochondrial Respiration Leads to Aortic Aneurysm

• Published in: Circulation (New York, N.Y.) Vol. 143; no. 21; pp. 2091 - 2109
• Main Authors: Oller, Jorge, Gabandé-Rodríguez, Enrique, Ruiz-Rodríguez, María Jesús, Desdín-Micó, Gabriela, Aranda, Juan Francisco, Rodrigues-Diez, Raquel, Ballesteros-Martínez, Constanza, Blanco, Eva María, Roldan-Montero, Raquel, Acuña, Pedro, Forteza Gil, Alberto, Martín-López, Carlos E., Nistal, J. Francisco, Lino Cardenas, Christian L., Lindsay, Mark Evan, Martín-Ventura, José Luís, Briones, Ana M., Miguel Redondo, Juan, Mittelbrunn, María
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 25.05.2021
• Subjects: Animals; Aortic Aneurysm - physiopathology; Disease Models, Animal; Humans; Marfan Syndrome - genetics; Marfan Syndrome - physiopathology; Mice; Mitochondria - metabolism; Original s; aortic aneurysm; genetic diseases, inborn; muscle, smooth, vascular; glycolysis; DNA, mitochondrial; Marfan syndrome; extracellular matrix
• DOI: 10.1161/CIRCULATIONAHA.120.051171
• ISSN: 0009-7322; 1524-4539

Marfan syndrome (MFS) is an autosomal dominant disorder of the connective tissue caused by mutations in the (fibrillin-1) gene encoding a large glycoprotein in the extracellular matrix called fibrillin-1. The major complication of this connective disorder is the risk to develop thoracic aortic aneurysm. To date, no effective pharmacologic therapies have been identified for the management of thoracic aortic disease and the only options capable of preventing aneurysm rupture are endovascular repair or open surgery. Here, we have studied the role of mitochondrial dysfunction in the progression of thoracic aortic aneurysm and mitochondrial boosting strategies as a potential treatment to managing aortic aneurysms. Combining transcriptomics and metabolic analysis of aortas from an MFS mouse model ( ) and MFS patients, we have identified mitochondrial dysfunction alongside with mtDNA depletion as a new hallmark of aortic aneurysm disease in MFS. To demonstrate the importance of mitochondrial decline in the development of aneurysms, we generated a conditional mouse model with mitochondrial dysfunction specifically in vascular smooth muscle cells (VSMC) by conditional depleting Tfam (mitochondrial transcription factor A; mice). We used a mouse model of MFS to test for drugs that can revert aortic disease by enhancing Tfam levels and mitochondrial respiration. The main canonical pathways highlighted in the transcriptomic analysis in aortas from mice were those related to metabolic function, such as mitochondrial dysfunction. Mitochondrial complexes, whose transcription depends on Tfam and mitochondrial DNA content, were reduced in aortas from young mice. In vitro experiments in -silenced VSMCs presented increased lactate production and decreased oxygen consumption. Similar results were found in MFS patients. VSMCs seeded in matrices produced by Fbn1-deficient VSMCs undergo mitochondrial dysfunction. Conditional Tfam-deficient VSMC mice lose their contractile capacity, showed aortic aneurysms, and died prematurely. Restoring mitochondrial metabolism with the NAD precursor nicotinamide riboside rapidly reverses aortic aneurysm in mice. Mitochondrial function of VSMCs is controlled by the extracellular matrix and drives the development of aortic aneurysm in Marfan syndrome. Targeting vascular metabolism is a new available therapeutic strategy for managing aortic aneurysms associated with genetic disorders.